

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Mesnex (mesna)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Comments	Quantity Limit
Mesnex (mesna) tablets	All Commercial, CCC, All MCD and HIX	May be subject to quantity limit
Mesnex (mesna) intravenous solution	All Commercial, CCC, AGP, VA MCD, HIX	

APPROVAL CRITERIA

Requests for Mesnex (mesna) may be approved if the following criteria are met:

- I. Individual is using as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis;
- OR**
- II. Individual is using as a prophylactic agent in reducing incidence of hemorrhagic cystitis in those receiving high-dose cyclophosphamide (AHFS);
- OR**
- III. Individual is using in combination with ifosfamide; **AND**
 - IV. Individual has a diagnosis of one of the following:
 - A. Ovarian Cancer (NCCN 2A); **OR**
 - B. Acute Lymphoblastic leukemia (NCCN 2A); **OR**
 - C. B-Cell Lymphomas (NCCN 2A); **OR**
 - D. Bladder cancer (NCCN 2A); **OR**
 - E. Bone cancer, including Ewing Sarcoma and Osteosarcoma (NCCN 2A); **OR**
 - F. Gestational Trophoblastic Neoplasia; **OR**
 - G. Hodgkin Lymphoma (NCCN 2A); **OR**
 - H. Penile Cancer (NCCN 2A); **OR**

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

- I. T-Cell Lymphomas (NCCN 2A); **OR**
- J. Testicular Cancer (NCCN 2A); **OR**
- K. Soft tissue sarcoma (NCCN 2A); **OR**
- L. Thymomas and Thymic Carcinomas; **OR**
- M. Uterine Neoplasms (NCCN 2A).

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018.
URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website.
<http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 2018.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.
5. The NCCN Drugs & Biologics Compendium (NCCN Compendium™) © 2018 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.